DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR ODEMA SECONDARY TO RETINAL VEIN OCCLUSION
RECOMMENDED ONLY IN LINE WITH THE CRITERIA GIVEN

<table>
<thead>
<tr>
<th>Name: generic (trade)</th>
<th>What it is</th>
<th>Indication</th>
<th>Date Decision last revised</th>
<th>Decision Status</th>
<th>NICE / SMC Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone intravitreal implant (Ozurdex)</td>
<td>Corticosteroid</td>
<td>Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)</td>
<td>August 2011</td>
<td>Final</td>
<td>NICE – TA229, recommended</td>
</tr>
</tbody>
</table>

HMMC Recommendation, following further clarification of NICE TAG229 with specialists: RECOMMENDED FOR RESTRICTED USE in line with NICE criteria.

Initiation Criteria
- Patient is over 18 years of age.
- Treatment should be in the worse-seeing eye only, unless patient is registered blind in one eye.
- Visual acuity in the eye to be treated is between 6/12 and 6/96.
- Further initiation criteria are as follows:

<table>
<thead>
<tr>
<th>BRVO</th>
<th>CRVO</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT ≥250 microns and haemorrhages are not masking fovea and no macular ischaemia on FFA.</td>
<td>OCT ≥250 microns and no macular ischaemia present on FFA.</td>
</tr>
</tbody>
</table>

Laser coagulation has been tried and was unsuccessful, or the extent of the disease makes laser photocoagulation unsuitable.

Re-treatment Criteria
Re-treatment of an eye previously treated with dexamethasone is only recommended:
- At an injection interval of >6 months.
- Where the treated eye showed an initial response to dexamethasone, assessed at day 60 after treatment, with best corrected visual acuity (BCVA) improvement of >15 letters, but has since deteriorated by >5 letters.
- For a maximum of 6 doses.

Further Criteria
- In line with the activity costs included in the economic evaluation which informed the NICE TA recommendation, commissioners would only expect to pay a day case tariff in 2012/13. From 2013/14 onwards, an outpatient activity tariff only will be paid. Any charges above this will require local contract negotiation.
- BCVA must be documented when treatment is given, 60 days after treatment and when treatment is repeated.

NICE criteria
- Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion (CRVO).
- Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch retinal vein occlusion (BRVO) when:
  - treatment with laser photocoagulation has not been beneficial, or
  - treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage.